<DOC>
	<DOCNO>NCT01542203</DOCNO>
	<brief_summary>This single site study conduct UT Southwestern Simmons Cancer Center . This study design measure drug concentration blood 18 female breast cancer patient require doxorubicin ( 30 minute infusion ) cyclophosphamide ( 30 minute infusion ) part standard medical care . Up total 40 adult female participant consent study cancer center . Eighteen participant need complete study . The others likely screen failure . The participant 100 ml blood drawn via peripheral intravenous catheter prior doxorubicin infusion , 0.5 , 1 , 1.5 , 2 , 3 , 4 , 5 , 12-24 , 24-72 h begin doxorubicin infusion . The 5 hour blood draw optional . The intravenous catheter remove participant discharged cancer center day 1 . The participant ask return cancer center 12-24 24-72 hour final 2 blood draw conduct . The participant must treat Doxorubicin Cyclophosphamide order participate pharmacokinetic analysis study .</brief_summary>
	<brief_title>Impact Body Weight Pharmacokinetic Analysis Doxorubicin + Cyclophosphamide Breast Cancer</brief_title>
	<detailed_description>The study require total 11 participant contact 3 day ( 1 day outpatient clinic visit doxorubicin cyclophosphamide infusion blood draw , 2 follow outpatient clinic visit blood draw ) 100 mL blood drawn . All blood draw collect purpose research . Screening Informed Consent Procedures 1 . The participant 's height , weight , medical history , comorbid condition , current medication obtain electronic medical record ( EMR ) . Update 1 : January 12 , 2012 2 . Study personnel provide participant additional information study provide participant opportunity ask question . Each participant ask willing provide inform consent . 3 . Information routine physical examination include vital sign ( temperature , respiratory rate , blood pressure , heart rate ) collect medical chart . Procedures Evaluation Research 1 . Each participant than10ml blood drawn 8 time , t=0h ( predose ) , end doxorubicin infusion , end cyclophosphamide infusion , 1.5 , 2 , 3 , 4 , 5 , 12-24 , 24-72 h follow begin doxorubicin infusion . All blood draw perform use peripheral intravenous catheter use standard medical care . Labels blood sample contain participant name , randomly generate participant identification number . 2 . All blood sample place ice immediately transport Dr. Richard Leff 's laboratory sample preparation.9 Samples spun refrigerate centrifuge place -80oC freezer . As explained , Dr. Leff laboratory access participant identifier . 3 . The participant discharge cancer center ( research purpose ) 4 hour blood draw , unless participant willing stay 5 hour blood draw . 4 . The participant return cancer center 12-24 24-72 hour blood draw . 5 . The participant discharge study 24-72h blood draw . Follow-up : Participants ask return cancer center 12-24 24-72 hour blood draw .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Body Weight</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Females , age 18 year age old , racial ethnic origin schedule receive first cycle single intravenous dose doxorubicin ( 30 minute infusion ) cyclophosphamide ( 30 minute infusion ) part standard medical care breast cancer . English and/or Spanish speaking participant eligible participate . Pregnant nursing unwilling use reliable contraception method study . The effect doxorubicin cyclophosphamide pregnancy unknown . In addition , metabolic change accompany pregnancy may alter concentrationtime profile doxorubicin cyclophosphamide , pregnancy postpartum state would confound variable . Participants unwilling comply study procedure . CrCl &lt; 10 ml/min Participants require peritoneal hemodialysis Serum bilirubin &gt; 1.19 mg/dL Receipt follow drug : Alter doxorubicin concentration : carbamazepine , cyclosporine , fosphenytoin , paclitaxel , phenytoin , sorafenib , valspodar , verapamil Alter cyclophosphamide concentration : cyclosporine , nevirapine , ondansetron All drug review screen patient</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>doxorubicin</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>BMI</keyword>
</DOC>